Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 20/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.72 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19544737 | 0.93 | ABL1 (0.87) | ABL1OPRM1KCNH2 | |
| SCHEMBL15391366 | 0.90 | ABL1 (1.00) | ABL1 | |
| SCHEMBL15392342 | 0.88 | ABL1 (1.00) | ABL1 | |
| SCHEMBL16714132 | 0.87 | ABL1 (1.00) | ABL1OPRM1KCNH2 | |
| SCHEMBL17561922 | 0.84 | ABL1 (0.82) | ABL1OPRM1KCNH2 | |
| SCHEMBL29771395 | 0.84 | ABL1 (1.00) | ABL1OPRM1KCNH2 | |
| SCHEMBL16714111 | 0.84 | ABL1 (1.00) | ABL1OPRM1KCNH2 | |
| SCHEMBL16714099 | 0.83 | ABL1 (1.00) | ABL1OPRM1KCNH2 | |
| SCHEMBL19545168 | 0.83 | ABL1 (0.71) | ABL1OPRM1KCNH2 | |
| SCHEMBL16860176 | 0.83 | ABL1 (0.90) | ABL1OPRM1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2900637-B1 | THIAZOLE OR IMIDAZOLE SUBSTITUTED PYRIMIDINE, PYRIDINE AND PYRAZINE AMIDE DERIVATIVES AND RELATED COMPOUNDS AS ABL1, ABL2 AND BCR-ABL1 INHIBITORS FOR THE TREATMENT OF CANCER, SPECIFIC VIRAL INFECTIONS AND SPECIFIC CNS DISORDERS | NOVARTIS AG (CH) | 2017-08-09 | — | — | EP | disclosed |
| EP-2900637-B1 | THIAZOLE OR IMIDAZOLE SUBSTITUTED PYRIMIDINE, PYRIDINE AND PYRAZINE AMIDE DERIVATIVES AND RELATED COMPOUNDS AS ABL1, ABL2 AND BCR-ABL1 INHIBITORS FOR THE TREATMENT OF CANCER, SPECIFIC VIRAL INFECTIONS AND SPECIFIC CNS DISORDERS | NOVARTIS AG (CH) | 2017-08-09 | — | — | EP | disclosed |
| US-9458112-B2 | Compounds and compositions for inhibiting the activity of ABL1, ABL2 and BCR-ABL1 | NOVARTIS AG (CH) | 2016-10-04 | — | — | US | disclosed |
| US-9458112-B2 | Compounds and compositions for inhibiting the activity of ABL1, ABL2 and BCR-ABL1 | NOVARTIS AG (CH) | 2016-10-04 | — | — | US | disclosed |
| US-9458112-B2 | Compounds and compositions for inhibiting the activity of ABL1, ABL2 and BCR-ABL1 | NOVARTIS AG (CH) | 2016-10-04 | — | — | US | disclosed |
| US-20160185733-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1 | NOVARTIS AG (CH) | 2016-06-30 | — | — | US | disclosed |
| US-20160185733-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1 | NOVARTIS AG (CH) | 2016-06-30 | — | — | US | disclosed |
| US-20160185733-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1 | NOVARTIS AG (CH) | 2016-06-30 | — | — | US | disclosed |
| US-9315489-B2 | Compounds and compositions for inhibiting the activity of ABL1, ABL2 and BCR-ABL1 | NOVARTIS AG (CH) | 2016-04-19 | — | — | US | disclosed |
| US-9315489-B2 | Compounds and compositions for inhibiting the activity of ABL1, ABL2 and BCR-ABL1 | NOVARTIS AG (CH) | 2016-04-19 | — | — | US | disclosed |
| US-9315489-B2 | Compounds and compositions for inhibiting the activity of ABL1, ABL2 and BCR-ABL1 | NOVARTIS AG (CH) | 2016-04-19 | — | — | US | disclosed |
| US-20150141427-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1 | NOVARTIS AG (CH) | 2015-05-21 | — | — | US | disclosed |
| US-20150141427-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1 | NOVARTIS AG (CH) | 2015-05-21 | — | — | US | disclosed |
| US-20150141427-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1 | NOVARTIS AG (CH) | 2015-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160185733-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1 | ABL1, ABL2, BCR | ABL1 1/4885OPRM1 3914/4885KCNH2 1726/4885 |
| US-20150141427-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1 | ABL1, ABL2, BCR | ABL1 1/4885OPRM1 3914/4885KCNH2 1726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.